Welcome to our dedicated page for Aveanna Healthcare Holdings news (Ticker: AVAH), a resource for investors and traders seeking the latest updates and insights on Aveanna Healthcare Holdings stock.
Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH) is described as a diversified home care platform focused on medically complex, high-cost patient populations, with headquarters in Atlanta, Georgia and locations in 38 states. The AVAH news page on Stock Titan aggregates company press releases and market updates that explain how Aveanna delivers pediatric and adult nursing, therapy, home health, hospice, and medical product services in home and community settings.
Visitors to this page can review Aveanna’s own announcements on topics such as updated full year financial guidance, preliminary and final quarterly results, and commentary on non-GAAP measures like EBITDA, Adjusted EBITDA, and Normalized Adjusted EBITDA. News items also cover participation in healthcare and finance conferences, including events hosted by financial institutions, where the company’s management presents to investors and holds one-on-one meetings.
Other Aveanna releases describe capital markets activity and financing developments, such as secondary offerings of common stock by existing stockholders and amendments to credit facilities and term loans. These updates provide context on the company’s capital structure, refinancing transactions, and relationships with lenders and underwriters.
Because Aveanna positions its services as a high quality, lower cost alternative to prolonged hospitalization, news about its financial performance, strategic financing actions, and investor presentations can be relevant to those tracking trends in home-based care for medically fragile and chronically ill children and adults. For ongoing coverage of AVAH, investors and observers can use this page to follow the company’s reported milestones, regulatory disclosures referenced in press releases, and other public communications.
Aveanna Healthcare (NASDAQ: AVAH) reported strong fourth-quarter and full-year 2025 results with meaningful revenue, profitability, and cash‑flow gains.
Q4 revenue was $662.5M (+27.4%), Q4 net income $178.8M, Q4 Adjusted EBITDA $85.0M (+54%). FY revenue was $2,433.2M (+20.2%) and FY Adjusted EBITDA $320.9M (+74.8%).
Company maintained 2026 guidance of $2.54–$2.56B revenue and $318–$322M Adjusted EBITDA, announced a $175.5M Family First Homecare acquisition expected to close in Q2 2026, and reported $131.0M free cash flow and $1,486.7M total indebtedness.
Aveanna Healthcare (NASDAQ: AVAH) agreed to acquire Family First Homecare, a pediatric private duty nursing provider with 27 locations in seven states. Aveanna plans to fund the deal with cash on hand and existing short-term credit borrowing. Closing is expected in Q2 2026, subject to customary conditions.
The acquisition expands Aveanna’s specialized pediatric footprint across Florida, Illinois, Iowa, Pennsylvania, South Dakota, Texas and North Carolina and follows Family First’s 2021 minority investment from Trivest Partners.
Aveanna (NASDAQ: AVAH) will release fourth quarter and full year 2025 results before market open on Thursday, March 19, 2026, followed by a conference call at 10:00 a.m. ET.
Investors can join by phone or webcast; a replay with passcode 13757396 will be available three hours after the call through March 26, 2026, and an online replay will remain for one week.
Aveanna Healthcare (NASDAQ: AVAH) announced that Aveanna Home Health and Hospice earned CHAP Disease Program Certification for Heart Failure on Feb 11, 2026. CHAP certification recognizes program structure, clinician education, quality metrics, and patient self-management tools under nationally recognized standards.
The certified Heartways program provides evidence-based care pathways for home health and hospice patients, aiming to reduce hospitalizations, improve symptom management, and strengthen patient and caregiver education.
Summary not available.
Aveanna (NASDAQ: AVAH) announced that management will attend the 44th Annual J.P. Morgan Healthcare Conference in San Francisco and will present on January 14, 2026.
The presentation is scheduled for 9:45 a.m. PST on January 14, 2026, followed by one-on-one investor meetings the same day. Interested parties can listen via a simultaneous webcast at https://ir.aveanna.com/. An online replay will be available for a limited time shortly after the call.
Aveanna (NASDAQ: AVAH) announced that management will participate virtually in the BofA Securities Home Care Conference on December 9, 2025.
Management will present at 12:30 PM ET, hold one-on-one investor meetings the same day, and offer a simultaneous webcast available via the company Investor Relations website with an online replay posted for a limited time.
Aveanna Healthcare (NASDAQ: AVAH) reported Q3 2025 revenue $621.9M (+22.2% YoY) and net income $14.1M versus a prior-year net loss. Q3 Adjusted EBITDA $80.1M (12.9% margin, +67.5% YoY). Nine-month revenue was $1.7707B (+17.7%) with Adjusted EBITDA $235.9M (+83.7%).
The company raised full-year 2025 guidance to revenue >$2.375B and Adjusted EBITDA >$300M. Liquidity: cash of $145.9M, securitization capacity $105.8M, undrawn revolver capacity ~$227M (≈$23M letters of credit). Total indebtedness was $1,490.0M; 2025 Term Loans bear interest at Term SOFR +3.75%. Free cash flow for nine months was $86.2M.
Aveanna Healthcare (NASDAQ: AVAH) announced the pricing of a secondary offering by selling stockholders affiliated with J.H. Whitney Equity Partners VII: 10,000,000 shares priced at $9.00 per share, with underwriters granted a 30-day option to buy up to an additional 1,500,000 shares.
The company will not sell shares or receive proceeds from the Offering. The sale is expected to settle on October 23, 2025, subject to customary closing conditions. A Form S-3 shelf registration (declared effective) and prospectus supplement are available through the SEC EDGAR system.
Aveanna Healthcare (NASDAQ: AVAH) announced on October 21, 2025 that certain selling stockholders affiliated with J.H. Whitney Equity Partners VII have commenced a secondary offering of 10,000,000 shares of common stock, with underwriters granted a 30-day option to purchase up to an additional 1,500,000 shares.
The selling stockholders will receive all net proceeds; the company is not offering shares and will not receive any proceeds from the sale. Jefferies and J.P. Morgan are joint lead book-running managers; Barclays and RBC are bookrunners. A Form S-3 shelf registration (including a prospectus) has been filed and declared effective by the SEC.